Pharmafile Logo

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

View the webcast »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time syndicated market tracking tool and Living Withdata, our syndicated patient report series shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This webcast, held in partnership with pharmaphorum uses the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Topics covered in the webcast include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKS compared to other new entrants and biosimilars
  • The patient profile and unmet needs in RA
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

View the webcast »

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

MedTech specialist joins Research Partnership

Janet Powers has joined the company as a Director in the MedTech division.

EVOKE MIND+MATTER BROADENS STRATEGIC CAPABILITY WITH FULL-SERVICE RESEARCH & INSIGHTS OFFERING

Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission...

Interactive: Best Behaviour

Download our curated collection of case studies and other useful resources that illustrate how we apply the principles of behavioural science in our research design.

RP Investigates – Q&A session: Living with Lupus

In this 45-minute session, Head of Living With, Mariel Metcalfe spoke to Brenda, who was diagnosed with Lupus 12 years ago.

Webcast: Demand Assessment

Find out how a study design which better reflects real-world choices can produce a more realistic model for the future market.

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

New syndicated patient report – Living with Lupus US

Living with Lupus US is a new syndicated patient report which offers valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.

Video: Emotion AI

Artificial intelligence is revolutionising the way we conduct healthcare market research.

Report: Mexico’s drug market access landscape shake-up: What does it mean for pharma?

Rebeca Nana Barrantes and Tania Rodrigues outline what the shake-up in Mexico’s drug market access landscape means for pharma.

Webcast: Virtual Q&A session – The future of digital health

In this webcast, Senior Director, Richard Head and Director of The Medical Futurist, Dr. Bertalan Mesko host a live virtual Q&A discussion about the future of digital health.